Is ASND a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Ascendis Pharma (ASND) rests on YORVIPATH is carrying the model: Hypoparathyroidism had no chronic hormone-replacement standard for years after Takeda withdrew Natpara, leaving a diagnosed population managed on calcium and active vitamin D. The bear case rests on revenue concentration is the dominant risk: one product supplies the large majority of sales, so a safety signal, a manufacturing interruption, or faster than expected competition in hypoparathyroidism would hit the whole model. Analysts covering it publish targets from $261.11 to $342.35 against a $271.19 share price on November 17, 2026, so even the professionals disagree by 27% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
ASND key stats
At $271.19 on November 17, 2026, Ascendis Pharma (ASND) has a market cap of $17.8B and a P/E of 20.8 on trailing earnings (27.1 on forward earnings).
- Market cap
- $17.8B
- P/E (trailing)
- 20.8
- P/E (forward)
- 27.1
- EPS (trailing 12 months)
- $13.05
- Price to book
- 11.0
Market cap, P/E and yield are measured at the $271.19 price on November 17, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Ascendis Pharma (ASND)?
The last two weeks for Ascendis Pharma, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- ASND closed at $271.19 on November 17, 2026, up 5.7% over the past five trading days (from $256.59).
- On November 12, 2026, Ascendis Pharma filed a current report (6-K) with the SEC. Read the 6-K on sec.gov
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Ascendis Pharma A/S trades on Nasdaq under ASND as American Depositary Shares, each representing one ordinary share of a company headquartered in Hellerup, Denmark. The business is built on TransCon, a prodrug technology that attaches a known parent drug to a carrier through a linker that releases the active molecule slowly and predictably, which lets Ascendis convert daily injections into weekly or monthly dosing. Three products are approved and marketed: SKYTROFA (lonapegsomatropin) for pediatric growth hormone deficiency, YORVIPATH (palopegteriparatide) for adult hypoparathyroidism, and YUVIWEL (navepegritide, developed as TransCon CNP), which received accelerated FDA approval with orphan exclusivity in May 2026 for pediatric achondroplasia. On October 16, 2026 the European Medicines Agency's CHMP issued a positive opinion recommending TransCon CNP for children with achondroplasia, the step that normally precedes a European Commission decision. Trailing twelve month revenue is roughly EUR 1.05 billion, with gross margin near 91 percent. The growth is concentrated in one product. In the first quarter of 2026 Ascendis reported total revenue of roughly EUR 247 million, of which YORVIPATH contributed roughly EUR 197 million and SKYTROFA roughly EUR 44 million. Second-quarter revenue rose to roughly EUR 340 million, up about 115 percent from a year earlier, and EPS of 0.90 beat the 0.77 consensus. Reported net profit of roughly EUR 629 million in the first quarter was dominated by a one-time recognition of a roughly EUR 679 million deferred tax asset, and management pointed to non-IFRS net profit of roughly EUR 18 million as the closer read on underlying operations that quarter. That distinction matters when reading the headline trailing price to earnings ratio near 17, because much of the trailing roughly EUR 742 million of net income is an accounting event rather than cash; trailing free cash flow is only about EUR 13 million. September 2026 brought two capital decisions. Ascendis and Novo Nordisk ended their collaboration, returning to Ascendis the rights to TransCon programs in metabolic and cardiovascular disease, including once-monthly TransCon Semaglutide for obesity and type 2 diabetes, with neither party carrying continuing financial obligations. Ascendis also announced a planned $400 million share repurchase program. The stock, worth about $14.9 billion, is up about 6% for 2026 and 9% over a year, but down about 11% over three months and well below its 52-week high of $282.15.
The bull case: what would have to be true for $342.35
The most optimistic published target on ASND is $342.35, +26.2% from the $271.19 share price on November 17, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. YORVIPATH is carrying the model
Hypoparathyroidism had no chronic hormone-replacement standard for years after Takeda withdrew Natpara, leaving a diagnosed population managed on calcium and active vitamin D. YORVIPATH stepped into that vacuum and grew to roughly EUR 197 million in the first quarter of 2026, and total company revenue reached roughly EUR 340 million in the second. Analysts expect about EUR 1.37 billion of 2026 revenue and about EUR 2.02 billion in 2027. The variables to watch are patient adds, persistence on therapy, and how much of the addressable population is reached before growth normalizes.
2. YUVIWEL opens a second large launch
Accelerated approval in May 2026 gave Ascendis a competitive entry in pediatric achondroplasia, a market BioMarin established with Voxzogo. The company reported more than 170 unique patient enrollments by June 30, 2026, with reimbursement approval above 65 percent, which is the early metric that matters because payer coverage gates conversion from enrollment to revenue. The October 2026 positive CHMP opinion opens the path to Europe. Two-year ApproaCH data on lower-extremity alignment is the clinical argument being used to differentiate, and Ascendis is presenting further achondroplasia and hypoparathyroidism data at ASBMR 2026.
3. Platform reuse lowers the cost of the next program
TransCon is applied to parent molecules whose biology is already validated, which shifts the risk profile toward formulation and dosing rather than target discovery. That has produced a pipeline reaching beyond endocrinology and rare disease into oncology candidates, and since September 2026 into metabolic disease on its own account: after the Novo Nordisk collaboration ended, Ascendis regained TransCon Semaglutide, a once-monthly prodrug candidate for obesity and type 2 diabetes, and said it plans multiple programs across rare and large indications. No development budget or clinical start date had been disclosed for the monthly candidate.
4. The path to sustained operating profitability
Gross margin near 91 percent is excellent, but commercial buildout across three simultaneous launches and continued research spending absorb much of the gross profit, and trailing free cash flow is only about EUR 13 million even though operating cash flow is about EUR 350 million. Yahoo's latest balance sheet shows about EUR 812 million of cash against about EUR 450 million of debt, a stronger position than earlier in the year, and the planned $400 million buyback signals management's confidence in cash generation. Analysts expect EPS to fall in 2027 from the tax-boosted 2026 level, so the timing of durable operating profit remains the key number.
The bear case: what would have to be true for $261.11
The most pessimistic published target is $261.11, -3.7% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Ascendis Pharma is worth if the risks below bite instead of the drivers above.
Revenue concentration is the dominant risk: one product supplies the large majority of sales, so a safety signal, a manufacturing interruption, or faster than expected competition in hypoparathyroidism would hit the whole model. AstraZeneca's eneboparatide and other parathyroid hormone programs target the same indication, while BioMarin's Voxzogo is entrenched in achondroplasia and a long-acting successor is in development, and oral FGFR3 approaches could reframe the category entirely; in October 2026 the FDA granted priority review to BridgeBio's achondroplasia filing. YUVIWEL was cleared under accelerated approval, which carries confirmatory evidence obligations that can constrain or withdraw a label. Taking back TransCon Semaglutide moves the cost and risk of an obesity program, a field crowded with the largest drugmakers, onto Ascendis alone. UBS cut its price target to $269 from $307 in October 2026. Ascendis is a foreign private issuer that reports in euros and files Form 20-F, so currency translation and a lighter interim disclosure cadence than a domestic filer both apply. On the legal side, Ascendis is an appellant in patent litigation against BioMarin at the Federal Circuit (No. 26-1026), and plaintiffs' firms publicized securities class action investigation notices in 2023 following the FDA deficiency letter on TransCon PTH, though those solicitations are not the same as a filed complaint and no active securities-fraud class action was identified as of August 2026.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding ASND already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on ASND
21 analysts cover ASND, with an average target of $304.78 (+12.4% against $271.19) and a split of 20 buy, 1 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the ASND forecast and price target page.
How is ASND valued?
Market cap, P/E and dividend yield at today's price are in the ASND key stats above. The business figures below come from Ascendis Pharma's reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~EUR 1.05 billion; Q2 2026 ~EUR 340 million, up ~115%
- Q2 2026 EPS: 0.90 vs ~0.77 consensus
- Profitability: Gross margin ~91%; TTM net income ~EUR 742 million, inflated by a ~EUR 679 million one-time tax asset
- Balance sheet: Cash ~EUR 812 million against debt ~EUR 450 million; $400 million buyback planned
- Cash flow (TTM): Operating cash flow ~EUR 350 million; free cash flow ~EUR 13 million
As of October 2026: The trailing earnings multiple is the number most likely to mislead here, because trailing net income is driven largely by the roughly EUR 679 million deferred tax asset recognized in the first quarter of 2026, not by operations. Price to sales near 14x and forward price to earnings near 21x are the cleaner framing, and both price in continued rapid growth; consensus calls for third-quarter revenue of about EUR 367 million. The mean analyst target of about $307 across 21 analysts sits well above the $226 share price.
How do you decide if ASND is a buy?
Whether ASND is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ASND indirectly through an index or sector ETF before adding more.
What would change your mind on ASND
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: YORVIPATH is carrying the model stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: revenue concentration is the dominant risk: one product supplies the large majority of sales, so a safety signal, a manufacturing interruption, or faster than expected competition in hypoparathyroidism would hit the whole model fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the ASND stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ASND against your real portfolio and see your actual exposure before deciding.
Your questions about Ascendis Pharma
Ask Walnut's AI anything about ASND and see how it fits what you own.
FAQ
Is ASND a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on YORVIPATH is carrying the model, with revenue (ttm) at ~EUR 1.05 billion; Q2 2026 ~EUR 340 million, up ~115%. The bear case rests on revenue concentration is the dominant risk: one product supplies the large majority of sales, so a safety signal, a manufacturing interruption, or faster than expected competition in hypoparathyroidism would hit the whole model. Analysts covering it are spread from $261.11 to $342.35, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell ASND?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Revenue concentration is the dominant risk: one product supplies the large majority of sales, so a safety signal, a manufacturing interruption, or faster than expected competition in hypoparathyroidism would hit the whole model. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $261.11, -3.7% from the $271.19 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.
What is the bull case for ASND?
+
YORVIPATH is carrying the model. Hypoparathyroidism had no chronic hormone-replacement standard for years after Takeda withdrew Natpara, leaving a diagnosed population managed on calcium and active vitamin D. The most optimistic analyst target on ASND is $342.35, +26.2% from the $271.19 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for ASND?
+
Revenue concentration is the dominant risk: one product supplies the large majority of sales, so a safety signal, a manufacturing interruption, or faster than expected competition in hypoparathyroidism would hit the whole model. AstraZeneca's eneboparatide and other parathyroid hormone programs target the same indication, while BioMarin's Voxzogo is entrenched in achondroplasia and a long-acting successor is in development, and oral FGFR3 approaches could reframe the category entirely; in October 2026 the FDA granted priority review to BridgeBio's achondroplasia filing. YUVIWEL was cleared under accelerated approval, which carries confirmatory evidence obligations that can constrain or withdraw a label. Taking back TransCon Semaglutide moves the cost and risk of an obesity program, a field crowded with the largest drugmakers, onto Ascendis alone. UBS cut its price target to $269 from $307 in October 2026. Ascendis is a foreign private issuer that reports in euros and files Form 20-F, so currency translation and a lighter interim disclosure cadence than a domestic filer both apply. On the legal side, Ascendis is an appellant in patent litigation against BioMarin at the Federal Circuit (No. 26-1026), and plaintiffs' firms publicized securities class action investigation notices in 2023 following the FDA deficiency letter on TransCon PTH, though those solicitations are not the same as a filed complaint and no active securities-fraud class action was identified as of August 2026. The most pessimistic published target is $261.11, -3.7% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.
What does Ascendis Pharma do?
+
Ascendis Pharma is a Danish biopharmaceutical company whose TransCon prodrug platform powers three approved rare-disease medicines: SKYTROFA, YORVIPATH and YUVIWEL.
What would have to change for ASND to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (YORVIPATH is carrying the model) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (revenue concentration is the dominant risk: one product supplies the large majority of sales, so a safety signal, a manufacturing interruption, or faster than expected competition in hypoparathyroidism would hit the whole model) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What company is ASND stock?
+
ASND is the Nasdaq ticker for Ascendis Pharma A/S, a biopharmaceutical company headquartered in Hellerup, Denmark. US investors hold American Depositary Shares rather than the Danish ordinary shares directly. The company uses its TransCon prodrug technology to develop long-acting versions of established therapies for rare endocrine and growth conditions.
What products does Ascendis Pharma sell?
+
Three approved products generate revenue. SKYTROFA (lonapegsomatropin) treats pediatric growth hormone deficiency, YORVIPATH (palopegteriparatide) treats adult hypoparathyroidism, and YUVIWEL (navepegritide) received accelerated FDA approval in May 2026 for pediatric achondroplasia and a positive CHMP opinion in Europe in October 2026. YORVIPATH is by far the largest contributor at roughly EUR 197 million in the first quarter of 2026.
Is Ascendis Pharma profitable?
+
It depends on which line you read. Trailing reported net income of roughly EUR 742 million is dominated by a one-time deferred tax asset recognition of roughly EUR 679 million in the first quarter of 2026. The company pointed to non-IFRS net profit of roughly EUR 18 million that quarter as the underlying figure, second-quarter EPS of 0.90 beat consensus, and trailing operating cash flow is about EUR 350 million, though free cash flow is close to breakeven.
Walnut is informational, not investment advice, and gives no verdict on ASND. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 17, 2026. Verify current figures with your broker before acting on them.